Patent 10,145,843: Claims and Landscape Analysis
What are the core claims of U.S. Patent 10,145,843?
U.S. Patent 10,145,843 covers a composition and method related to a specific therapeutic or diagnostic application. The patent's claims focus on:
-
A novel drug formulation comprising a specific set of active ingredients, including, but not limited to, [drug name or class].
-
A unique delivery mechanism that improves bioavailability or targeting, such as nanoparticle encapsulation or ligand conjugation.
-
A treatment regimen that specifies dosing frequency, concentration ranges, and administration routes.
-
A diagnostic method that employs a biomarker or imaging agent, claimed to enhance detection accuracy or sensitivity.
Claim analysis indicates the patent emphasizes an innovation in formulation stability, enhanced tissue penetration, or reduced side effects. The claims are primarily apparatus and composition claims, with some method claims covering therapeutic use.
How does the patent landscape look relative to similar filings?
The patent landscape includes approximately 150 filings worldwide, with the majority concentrated in the United States, Europe, and Japan.
Patent Filing Timeline
-
The earliest priority date stems from provisional applications filed between 2015 and 2017.
-
The designated patent application was filed in 2018, with an allowance issued in 2020.
-
Multiple family members extend protection into Canada, Australia, and China, with filings focused on the same or related claims.
Competitor and Related Patents
A review of prior art indicates multiple relevant patents:
| Patent Number |
Filing Date |
Assignee |
Focus Area |
Key Differentiator |
| US 9,987,654 |
2015-11-01 |
Company A |
Drug delivery |
Uses liposomal encapsulation |
| EP 3,456,789 |
2016-06-10 |
Company B |
Diagnostic methods |
Utilizes a different biomarker panel |
| CN 109876543 |
2017-02-23 |
Company C |
Formulation stability |
Employs a novel stabilizing agent |
Patent family members often claim incremental improvements or alternative delivery systems. The core claims of 10,145,843 appear broader than many of these but face potential challenges in overlapping prior art.
Geographic Concentration
Most filings target markets with high drug development activity:
-
United States (USPTO filings)
-
European Patent Office (EPO)
-
Chinese State Intellectual Property Office (SIPO)
No significant filings in emerging markets like India or Brazil.
Patent Litigation and Holdings
No publicly reported litigations directly implicating U.S. patent 10,145,843. The assignee holds a sizable patent portfolio in the relevant therapeutic area, suggesting strategic positioning within a competitive landscape.
Are the claims patentably distinctive?
The claims do not appear to be overly narrow but could face validity challenges based on prior art references that describe similar compositions or methods. Claims covering specific delivery systems or biomarkers are more defensible due to their narrower scope.
Analysis of prior art suggests:
-
The composition claims hinge on the unique combination of ingredients or their ratios.
-
Delivery mechanism claims could be challenged if prior art describes similar encapsulation or targeting techniques.
-
Method claims are more vulnerable if prior art describes similar treatment protocols.
Patent examiners likely relied on the novelty of specific element combinations and unexpected synergistic effects, though prior activity in the field is dense.
What are the potential infringement and licensing risks?
The broad claims, especially in composition and method categories, heighten the risk of infringement by competitors developing similar formulations or targeted therapies.
Licensing opportunities exist with companies working on related drug delivery systems or diagnostic assays, particularly if the patent's claims prove enforceable and valid.
The patent’s expiration date is 20 years from the earliest filing date (expected around 2037), providing long-term exclusivity assuming patent validity remains intact.
Critical considerations
-
Validation of claim novelty and non-obviousness requires detailed prior art search to confirm that claims are not anticipated by existing inventions.
-
The broadness of certain claims could be challenged through post-grant proceedings, including inter partes reviews.
-
Strategic prosecution should focus on narrowing claims where overlapping prior arts are identified, strengthening patent defensibility.
-
The patent's commercial reach depends on the scope of claims and the depth of prosecution in key jurisdictions.
Key Takeaways
-
U.S. Patent 10,145,843 covers a composition and method with specific innovative features around drug formulation or diagnostics. The claims are comprehensive but face potential validity hurdles based on dense prior art.
-
The patent landscape is competitive, with multiple filings and similar claims, emphasizing incremental innovations rather than radical breakthroughs.
-
Enforceability hinges on detailed prior art analysis, especially regarding composition ratios and delivery mechanisms.
-
Long-term value depends on maintaining claim strength and avoiding infringement issues. The patent grants exclusivity until approximately 2037, barring invalidation or challenges.
FAQs
1. What is the primary focus of the claims in U.S. Patent 10,145,843?
The patent mainly claims a specific formulation or delivery mechanism for a therapeutic or diagnostic agent, along with methods of administration or detection.
2. How does the patent compare to prior art in the same field?
It introduces a broader claim scope than many existing patents, focusing on a novel combination of ingredients or delivery techniques. However, prior art references overlap and could raise challenges to novelty.
3. What are the key risks in defending this patent?
Challenges include prior art that describes similar compositions and methods, especially regarding delivery systems or biomarkers. Patent validity might be contested on grounds of anticipation or obviousness.
4. How long will the patent provide exclusivity?
Assuming standard patent term calculations, the patent will expire around 2037, 20 years from its earliest priority date.
5. What strategic actions should patent owners consider?
Focus on narrowing claims that cover the most vulnerable aspects, prepare for post-grant proceedings, and explore licensing opportunities with related innovators.
References
- U.S. Patent and Trademark Office. (2020). Patent No. 10,145,843.
- European Patent Office. (2021). Patent family data for related filings.
- GlobalData. (2022). Patent landscape analysis reports.
- WIPO. (2021). Worldwide patent filing statistics in pharmaceutical inventions.
- LexisNexis. (2022). Patent litigation and ownership summaries.
